Fatty liver disease (MASLD/MASH): who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• PPAR 1
• AMPK 0
• GLP-1 7
• SGLT2 5
• NRF2 1
• SIRT1 0
• PNPLA3 6
• NLRP3 1
• mTOR 0
• AKT 0
• PI3K 0
• STAT3 0
• TLR4 0
• MAPK 0
• STING 0
• JNK 0
• TP53 0
• PINK1 0
• TNF 2
• HIF-1 0
• JAK 0
• GIP 1
• TFEB 0
• YAP 0
• CTNNB1 0
• ERK 0
• COX-2 0
• HSP90 0
• PTEN 0
• STK11 0
• APOE 0
• FTO 0
• HMGB1 0
• IL-6 0
• KEAP1 0
• PCSK9 0
• DPP-4 0
• GPX4 0
• VEGF 0
• FGFR 0
• IL-17 0
• PDGFR 0
• BDNF 0
• IL-1 0
• METTL3 0
• PKM2 0
• TREM2 0
• ACE2 0
• EGFR 0
• FAK 0
• IDH 0
• IDO1 0
• MDM2 0
• PARP 0
• PD-1 0
• RANKL 1
• ABL1 0
• ALK 0
• BCL-2 0
• CD38 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Subcellular Lipid Atlas: Decoding Organelle Identity with Targeted Lipid Profiling (LipID)

  Universitat Wien· Wien, Austria· EU contribution €1,500,000· until Jun 2032· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Metabolic Hepatoprotection to Enable Curative Cancer Therapy in Patients with Vulnerable Livers (SAFE-LIVER)

  Universitaet Bern· Bern, Switzerland· EU contribution €150,000· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Epigenomic Liquid Biopsy for Early Detection and Monitoring of Metabolic Dysfunction-Associated Steatohepatitis (cfChIP-MASH)

  The Hebrew University of Jerusalem· Jerusalem, Israel· EU contribution €150,000· until Jan 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Crossing borders of liver and adipose tissue (mis)communication: a novel translational approach to study molecular mechanisms and targets in metabolic dysfunction-associated steatotic liver disease (XB-LIVAT)

  Fondazione Italiana Fegato E.t.s.· Trieste, Italy· EU contribution €193,643· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploring the impact of Time-Restricted Eating and Exercise interventions on Gut microbiome of patients with hepatic steatosis and obesity – TREEGut

  Universidad de Granada· Granada, Spain· EU contribution €194,075· until Dec 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Human-based methodologies to study toxicity of food nanoparticles on fatty liver diseases via the microbiota-bile acid axis. (nanoBASH)

  Universite Catholique de Louvain· Louvain la Neuve, Belgium· EU contribution €1,500,000· until Dec 2030

• European Commission (Horizon Europe) · HORIZON-ERC

  Fatty liver versus autoimmunity of the bile ducts - defining the gut signals driving steatosis and inflammatory disease of the gut-liver axis (FatVersusBile)

  Universitetet I Oslo· Oslo, Norway· EU contribution €2,000,000· until Apr 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Defining the role of stromal cells in determining HCC patient response to immunotherapies at single-cell resolution (STRIM-HCC)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €194,075· until Mar 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Scalable target identification for metabolic liver disease (3DMASH)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,950,000· until Jan 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Promoting RObust Systems biology on Patients and Experimental models with obesity-driven liveR cancer (PROSPER)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €183,601· until Dec 2026

  The disease is named only in the funder's project summary, not in the title.

10 of 22 running projects, newest first. Listed amounts together: €71.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

  NCT07567378· JULIO GRANADOS MONTIEL· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 17
• Mendelian Randomization Analysis 45
• CRISPR-Cas Systems 3
• Gene Expression Profiling 105
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 3
• Exome Sequencing 2
• Proteomics 66
• Metabolomics 104
• Mass Spectrometry 10
• Flow Cytometry 3
• Immunohistochemistry 16
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 103
• Machine Learning 103
• Deep Learning 14
• Cohort Studies 172
• Genome-Wide Association Study 49

• Integrated Transcriptomic and Single-Cell Analysis Reveals Shared Macrophage-Associated Inflammatory Signatures in MASLD/NAFLD and Rheumatoid Arthritis.

  Int J Mol Sci, Oct 2026

• A human single-cell atlas identifies OLR1+ scar-associated macrophages as a potential therapeutic target for chronic liver disease.

  Nat Genet, Sept 2026

• An lncRNA-aware single-cell framework with donor-level validation identifies reproducible MEG3 enrichment in human liver sinusoidal endothelial cells.

  Funct Integr Genomics, Sept 2026

• Cell-type-specific damage scores reveal kidney and liver disease trajectories in single-cell and spatial transcriptomics.

  Cell Genom, Aug 2026

• Identification of glutathione metabolism-related biomarkers in non-alcoholic fatty liver disease based on single-cell and bulk RNA sequencing.

  BMC Med Genomics, Jul 2026

• Bisphenol A drives the comorbidity of non-alcoholic fatty liver disease and osteoarthritis by targeting RHOB: Integrated multi-omics, single-cell analysis, and experimental validation.

  Exp Gerontol, Jul 2026

• Potential targets of baicalein in macrophages revealed by bulk and single cell RNA sequencing analysis.

  Naunyn Schmiedebergs Arch Pharmacol, Jun 2026

• Integrative Single-Cell Transcriptomic, Mendelian Randomization and In Silico Perturbation Analyses Prioritize MUC20 as a Candidate Gene Associated with Osteoporosis and Metabolic Dysfunction-Associated Steatotic Liver Disease in the Liver-Bone Axis.

  Int J Mol Sci, Jun 2026

• Identification of Estrogen-Related Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease Through Machine Learning and Single-Cell Analysis.

  Clin Transl Gastroenterol, Jun 2026

• A fluorescence-based high-content imaging workflow for multi-parametric lipid droplet phenotyping via Oil Red O fluorescence.

  Methods, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.